Type 2 diabetes mellitus and its vascular complications
Conditions
Interventions
Experimental group:Dulaglutide (0.75mg - 1.5mg once a week, subcutaneous injection)
Control group:Metformin (1.5g - 2.0g per day, taken orally)
Sponsors
The First Affiliated Hospital of Chengdu Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for type 2 diabetes; 2. Glycated hemoglobin<9%; 3. Sign an informed consent form to reach the age of 18-80 years old; 4.Before participating in the screening, the patient or their guardian has signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Participants in intervention research; Those who use Liraglutide, SGLT-2i, and DPP4i; 2. Pregnant women, lactating women, pregnant women with diabetes or diabetes with pregnancy; 3. Severe kidney disease, eGFR<15mlmin/1.73m^2; 4. Tumor chemotherapy and radiotherapy status; 5. Individuals who are allergic to GLP-1 receptor agonists; 6. Patients who are unable or unwilling to cooperate due to the merger of other mental illnesses; Or other situations that the researcher deems unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Surface markers of endothelial progenitor cells(CD34+ and CD133+);Stromal cell-derived factor-1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Endothelial nitric oxide synthase;Nitric oxide;Interleukin-6;Interleukin-8;Tumor necrosis factor-a;Interleukin-4;Interleukin-10;Transforming growth factor-ß;Glycosylated hemoglobin;Liver function;Renal function;Blood lipids;Urine albumin/urine creatinine ratio;Visceral fat measure;Intima-media thickness of the carotid artery;Ankle-brachial blood pressure index; | — |
Countries
China
Contacts
Public ContactMei Xi
The First Affiliated Hospital of Chengdu Medical College
Outcome results
None listed